Thiotepa Incorporating TBI/Cy Conditioning Regimen for EBV-HLH With Central Nervous System Involvement
Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
EBV-HLH is the most common in virus-associated hemophagocytic syndrome (VAHS). There are no
uniform clinical criteria for the diagnosis of CNS-HLH. And there is still a lack of
international consensus on the treatment for CNS-HLH. Following allogeneic HSCT after HLH
induction therapy is recommended for CNS-HLH. One of the major factors influencing the
transplantation effect is conditioning. Therefore, we conduct a prospective clinical study to
explore the efficacy and safety of thiotepa incorporating TBI/Cy conditioning regimen
followed by allogeneic hematopoietic stem cell transplantation for EBV-HLH with central
nervous system involvement.